3 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaDigestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, pancreatic neoplasmRecruitingPhase 32026-10-09NCT07562152
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With CancerneoplasmRecruitingPhase 22026-08-07NCT05999994
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Carcinoma, Medullary, Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Thyroid Cancer, Papillary, adenocarcinoma, breast disorder, breast neoplasm, bronchial disorder, bronchial neoplasm, bronchogenic carcinoma, carcinoma, central nervous system cancer, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, intestinal disorder, lung disorder, lung neoplasm, malignant colon neoplasm, malignant endocrine neoplasm, medullary thyroid gland carcinoma, neoplasm, nervous system disorder, neuroendocrine carcinoma, neuroendocrine neoplasm, non-small cell lung carcinoma, papillary adenocarcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, skin disorder, thyroid gland disorder, thyroid tumorActive, not recruitingPhase 1 / Phase 22026-04-16NCT03157128